Close
Mark Jit

Professor of Vaccine Epidemiology

Education

Affiliations

Projects

Papers

Abbas KM, van Zandvoort K, Brisson M, Jit M. (2020). Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study. The Lancet. Global health

Tam CC, Yeo KT, Tee N, Lin R, Mak TM, Thoon KC, Jit M, Yung CF. (2020). Burden and Cost of Hospitalization for Respiratory Syncytial Virus in Young Children, Singapore. Emerging infectious diseases, 26(7)

Baral R, Li X, Willem L, Antillon M, Vilajeliu A, Jit M, Beutels P, Pecenka C. (2020). The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models. Vaccine

Davies NG, Klepac P, Liu Y, Prem K, Jit M, , Eggo RM. (2020). Age-dependent effects in the transmission and control of COVID-19 epidemics. Nature medicine

Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, Sanderson C, McKee M, Troeger C, Ong KL, Checchi F, Perel P, Joseph S, Gibbs HP, Banerjee A, Eggo RM,. (2020). Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. The Lancet. Global health

Portnoy A, Clark S, Ozawa S, Jit M. (2020). The impact of vaccination on gender equity: conceptual framework and human papillomavirus (HPV) vaccine case study. International journal for equity in health, 19(1)

Li X, Willem L, Antillon M, Bilcke J, Jit M, Beutels P. (2020). Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries. BMC medicine, 18(1)

Jit M, Jombart T, Nightingale ES, Endo A, Abbott S, Lshtm Centre For Mathematical Modelling Of Infectious Diseases Covid-Working Group, Edmunds WJ. (2020). Estimating number of cases and spread of coronavirus disease (COVID-19) using critical care admissions, United Kingdom, February to March 2020. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 25(18)

Luyten J, Kessels R, Atkins KE, Jit M, van Hoek AJ. (2019). Quantifying the public's view on social value judgments in vaccine decision-making: A discrete choice experiment. Social science & medicine (1982), (228)

Jit M, Flasche S. (2019). The role of pneumococcal conjugate vaccination in reducing pneumonia mortality. The Lancet. Global health, 7(2)

Bains I, Choi YH, Soldan K, Jit M. (2019). Clinical impact and cost-effectiveness of primary cytology versus human papillomavirus testing for cervical cancer screening in England. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Clark A, Tate J, Parashar U, Jit M, Hasso-Agopsowicz M, Henschke N, Lopman B, Van Zandvoort K, Pecenka C, Fine P, Sanderson C. (2019). Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules. The Lancet. Global health, 7(11)

Takwoingi Y, Whitworth H, Rees-Roberts M, Badhan A, Partlett C, Green N, Boakye A, Lambie H, Marongiu L, Jit M, White P, Deeks JJ, Kon OM, Lalvani A. (2019). Interferon gamma release assays for Diagnostic Evaluation of Active tuberculosis (IDEA): test accuracy study and economic evaluation. Health technology assessment (Winchester, England), 23(23)

Sim SY, Jit M, Constenla D, Peters DH, Hutubessy RCW. (2019). A Scoping Review of Investment Cases for Vaccines and Immunization Programs. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 22(8)

Markowitz LE, Drolet M, Perez N, Jit M, Brisson M. (2018). Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine, 36(32 Pt A)

Howard N, Bell S, Walls H, Blanchard L, Brenzel L, Jit M, Mounier-Jack S. (2018). The need for sustainability and alignment of future support for National Immunization Technical Advisory Groups (NITAGs) in low and middle-income countries. Human vaccines & immunotherapeutics, 14(6)

Jit M, Brisson M. (2018). Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirus. International journal of cancer, 143(2)

Sandmann FG, Shallcross L, Adams N, Allen DJ, Coen PG, Jeanes A, Kozlakidis Z, Larkin L, Wurie F, Robotham JV, Jit M, Deeny SR. (2018). Estimating the Hospital Burden of Norovirus-Associated Gastroenteritis in England and Its Opportunity Costs for Nonadmitted Patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 67(5)

Bate J, Baker S, Breuer J, Chisholm JC, Gray J, Hambleton S, Houlton A, Jit M, Lowis S, Makin G, O'Sullivan C, Patel SR, Phillips R, Ransinghe N, Ramsay ME, Skinner R, Wheatley K, Heath PT. (2019). PEPtalk2: results of a pilot randomised controlled trial to compare VZIG and aciclovir as postexposure prophylaxis (PEP) against chickenpox in children with cancer. Archives of disease in childhood, 104(1)

Murray ML, Meadows J, Doré CJ, Copas AJ, Haddow LJ, Lacey C, Jit M, Soldan K, Bennett K, Tetlow M, Nathan M, Gilson R. (2018). Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial). BMC medical research methodology, 18(1)

Bissett SL, Godi A, Jit M, Beddows S. (2017). Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis. Vaccine, 35(32)

Van Minh H, My NTT, Jit M. (2017). Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study. BMC health services research, 17(1)

Sandmann FG, Robotham JV, Deeny SR, Edmunds WJ, Jit M. (2018). Estimating the opportunity costs of bed-days. Health economics, 27(3)

Wong JJ, Jit M, Sultana R, Mok YH, Yeo JG, Koh JWJC, Loh TF, Lee JH. (2019). Mortality in Pediatric Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis. Journal of intensive care medicine, 34(7)

Ng D, Ghosh A, Jit M, Seneviratne SL. (2017). Mini-review: Can non-human leucocyte antigen genes determine susceptibility to severe dengue syndromes?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 111(9)

Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. (2017). Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. The Lancet. Public health, 2(8)

Recker M, Vannice K, Hombach J, Jit M, Simmons CP. (2016). Assessing dengue vaccination impact: Model challenges and future directions. Vaccine, 34(38)

Loganathan T, Ng CW, Lee WS, Jit M. (2016). The Hidden Health and Economic Burden of Rotavirus Gastroenteritis in Malaysia: An Estimation Using Multiple Data Sources. The Pediatric infectious disease journal, 35(6)

Jit M. (2016). The economic burden of dengue: no longer invisible or unavoidable. The Lancet. Infectious diseases, 16(8)

Atkins K, van Hoek AJ, Watson C, Baguelin M, Choga L, Patel A, Raj T, Jit M, Griffiths U. (2016). Seasonal influenza vaccination delivery through community pharmacists in England: evaluation of the London pilot. BMJ open, 6(2)

Ong KJ, Soldan K, Jit M, Dunbar JK, Woodhall SC. (2017). Chlamydia sequelae cost estimates used in current economic evaluations: does one-size-fit-all?. Sexually transmitted infections, 93(1)

King EM, Oomeer S, Gilson R, Copas A, Beddows S, Soldan K, Jit M, Edmunds WJ, Sonnenberg P. (2016). Oral Human Papillomavirus Infection in Men Who Have Sex with Men: A Systematic Review and Meta-Analysis. PloS one, 11(7)

Wu JT, Jit M, Zheng Y, Leung K, Xing W, Yang J, Liao Q, Cowling BJ, Yang B, Lau EH, Takahashi S, Farrar JJ, Grenfell BT, Leung GM, Yu H. (2016). Correction: Routine Pediatric Enterovirus 71 Vaccination in China: a Cost-Effectiveness Analysis. PLoS medicine, 13(4)

Jit M, Dang TT, Friberg I, Hoang VM, Pham Huy TK, Walker N, Nguyen VC, Tran ND, Toda K, Hutubessy R, Fox K, Nguyen TH. (2015). Thirty years of vaccination in Vietnam: Impact and cost-effectiveness of the national Expanded Programme on Immunization. Vaccine, (33 Suppl 1)

Portnoy A, Jit M, Lauer J, Blommaert A, Ozawa S, Stack M, Murray J, Hutubessy R. (2015). Estimating costs of care for meningitis infections in low- and middle-income countries. Vaccine, (33 Suppl 1)

Ultsch B, Damm O, Beutels P, Bilcke J, Brüggenjürgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, Knol M, von Kries R, Kuhlmann A, Levy-Bruhl D, Perleth M, Postma M, Salo H, Siebert U, Wasem J, Wichmann O. (2016). Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. PharmacoEconomics, 34(3)

Jit M. (2015). High-dose influenza vaccines make economic sense for older people. The Lancet. Infectious diseases, 15(12)

Jit M, Franco E, Jha P. (2015). What makes an eLife paper in epidemiology and global health?. eLife, (4)

Jit M, Brisson M, Laprise JF, Choi YH. (2015). Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ (Clinical research ed.), (350)

Mendes D, Bains I, Vanni T, Jit M. (2015). Systematic review of model-based cervical screening evaluations. BMC cancer, (15)

Verguet S, Johri M, Morris SK, Gauvreau CL, Jha P, Jit M. (2015). Controlling measles using supplemental immunization activities: a mathematical model to inform optimal policy. Vaccine, 33(10)

Quinn E, Jit M, Newall AT. (2014). Key issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination. Expert review of pharmacoeconomics & outcomes research, 14(3)

Jit M, Choi YH, Laprise JF, Boily MC, Drolet M, Brisson M. (2014). Two-dose strategies for human papillomavirus vaccination: how well do they need to protect?. Vaccine, 32(26)

Oppong R, Jit M, Smith RD, Butler CC, Melbye H, Mölstad S, Coast J. (2013). Cost-effectiveness of point-of-care C-reactive protein testing to inform antibiotic prescribing decisions. The British journal of general practice : the journal of the Royal College of General Practitioners, 63(612)

Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. (2012). Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. The Lancet. Infectious diseases, 12(10)

Baguelin M, Jit M, Miller E, Edmunds WJ. (2012). Health and economic impact of the seasonal influenza vaccination programme in England. Vaccine, 30(23)

van Hoek AJ, Choi YH, Trotter C, Miller E, Jit M. (2012). The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. Vaccine, 30(50)

Newall AT, Jit M, Beutels P. (2012). Economic evaluations of childhood influenza vaccination: a critical review. PharmacoEconomics, 30(8)

Choi YH, Jit M, Flasche S, Gay N, Miller E. (2012). Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales. PloS one, 7(7)

Choi YH, Chapman R, Gay N, Jit M. (2012). Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: quantification using a multi-type mathematical model. Vaccine, 30(23)

Jit M, Chapman R, Hughes O, Choi YH. (2011). Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ (Clinical research ed.), (343)

Chapman R, Soldan K, Jit M. (2011). Modelling borderline and mild dysplasia associated with HPV 6 and 11 infection. Vaccine, 29(16)

Jit M, Brisson M. (2011). Modelling the epidemiology of infectious diseases for decision analysis: a primer. PharmacoEconomics, 29(5)

Jit M, Demarteau N, Elbasha E, Ginsberg G, Kim J, Praditsitthikorn N, Sinanovic E, Hutubessy R. (2011). Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC medicine, (9)

Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ. (2010). Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine, 28(24)

Jit M, Bilcke J, Mangen MJ, Salo H, Melliez H, Edmunds WJ, Yazdan Y, Beutels P. (2009). The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. Vaccine, 27(44)

Jit M, Pebody R, Chen M, Andrews N, Edmunds WJ. (2007). Estimating the number of deaths with rotavirus as a cause in England and wales. Human vaccines, 3(1)